KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
26.66
+0.01 (0.04%)
At close: May 4, 2026, 4:00 PM EDT
26.58
-0.08 (-0.30%)
After-hours: May 4, 2026, 7:56 PM EDT
KalVista Pharmaceuticals Employees
KalVista Pharmaceuticals had 275 employees as of December 31, 2025. The number of employees increased by 5 or 1.85% since the number was reported on April 30, 2025.
Employees
275
Change
5
Growth
1.85%
Revenue / Employee
$267,698
Profits / Employee
-$597,404
Market Cap
1.37B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 275 | 5 | 1.85% |
| Apr 30, 2025 | 270 | 120 | 80.00% |
| Apr 30, 2024 | 150 | 32 | 27.12% |
| Apr 30, 2023 | 118 | 13 | 12.38% |
| Apr 30, 2022 | 105 | 35 | 50.00% |
| Apr 30, 2021 | 70 | 14 | 25.00% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 749 |
| AbCellera Biologics | 562 |
| Wave Life Sciences | 317 |
| Viridian Therapeutics | 252 |
| uniQure | 221 |
| MapLight Therapeutics | 133 |
| ArriVent BioPharma | 77 |
| GH Research | 73 |
KALV News
- 5 days ago - Italian drugmaker Chiesi to buy KalVista for $1.9 billion - Reuters
- 5 days ago - Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio - Business Wire
- 5 days ago - Italian pharma group Chiesi to buy US peer KalVista for $1.9 billion - Reuters
- 19 days ago - KalVista Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 26 days ago - KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference - Business Wire
- 5 weeks ago - KalVista Pharmaceuticals Transcript: Transition period - Transcripts